Targacept/AstraZeneca Alzheimer's hope fails in Phase II
This article was originally published in Scrip
Executive Summary
Targacept and AstraZeneca's investigational Alzheimer's disease drug ispronicline has failed to show improvement over placebo in a Phase IIb study.